Astrazeneca chief blasts Europe for ‘putting citizens’ health at risk’ healthcare Europe is putting its “ability to protect the health of its own people at risk” by not investing enough, the chief executive of FTSE 100 giant Astrazeneca has warned. Pascal Soriot added that the continent is “falling behind” in attracting R&D and manufacturing investment and needs to “invest more in what really matters to it”. [...]
As FTSE 100 pharma firms wait for a tariffs decision, what would drugs levies mean for consumers? pharma For FTSE 100 businesses navigating the shifting sands of Trump’s trade war, the uncertainty surrounding the tariffs has been almost as painful as the stock market shocks. The pharmaceutical industry has been left in a particularly agonising limbo: free, for now, from the 10 per cent baseline import tax, but the US President keeps making [...]
Government scrambles to swerve Trump pharma tariffs Politics A race against time is underway to shield the UK pharmaceutical sector from potentially swinging Trump tariffs on imported drugs. As it stands, there is an exemption for pharmaceuticals on the baseline 10 per cent tariffs for goods coming into the US. However, President Trump has warned that there will be tariffs on imported pharma [...]
FTSE 100 pharma giants GSK and Astrazeneca appear to swerve Trump tariffs April 3, 2025 FTSE 100 pharma giants GSK and Astrazeneca may have escaped the worst of US President Donald Trump’s tariffs, according to a City broker. Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his Rose Garden ‘Liberation Day’ address on Wednesday, but there is still uncertainty about the impact on the [...]
US tariffs: Keir Starmer vows to ‘keep cool head’ in face of ‘economic impact’ April 3, 2025 Sir Keir Starmer has vowed to “keep a cool head” in the face of the “economic impact” of Donald Trump’s 10 per cent tariffs on UK exports to the US, amid fears of a wider trade war. The Prime Minister spoke to business chiefs in Downing Street this morning in the wake of sweeping global [...]
Astrazeneca: ‘We’re too big to base our CEO’s pay on FTSE 100 peers’ February 18, 2025 Astrazeneca is too big and complex to base its chief executive’s pay packet on the rest of the FTSE index, according to the chair of its remuneration committee. Writing in the pharmaceutical giant’s annual report, chair Sheri McCoy said “UK-listed FTSE companies are not the right peer group for us to use” given the group’s [...]
Astrazeneca revenue surges amid Chinese import tax allegations February 6, 2025 Astrazeneca’s revenue jumped 21 per cent last year despite growing troubles over its presence in China. The pharmaceutical giant recorded $54bn (£43.3bn) in revenue for the year, a jump of 21 per cent on 2023’s levels. In its full-year results, the largest FTSE 100 firm revealed that revenue in Europe had skyrocketed 37 per cent. [...]
Astrazeneca: FTSE 100 giant shrugs off China worries with profit upgrade November 12, 2024 Pharmaceuticals giant Astrazeneca has reported double-digit sales growth on higher demand and said it remains committed to China despite the detention of a high-ranking staff member there. The FTSE 100 firm told markets this morning that total revenue rose 19 per cent to $39.2bn (£30.6bn) in the first nine months of the year. The London-listed [...]
US approves Astrazeneca lung cancer drug Imfinzi for treatment August 16, 2024 Astrazeneca’s lung cancer drug Imfinzi has been approved for treatment in the US to be used both before and after surgery, just days after the company’s market value hit £200bn for the first time. Imfinzi, which is meant to treat early-stage non-small cell lung cancer alongside chemotherapy, is administered before and after surgery. The approval [...]
How Astrazeneca became the London Stock Exchange’s newest £200bn firm August 14, 2024 Astrazeneca has become the most recent UK-listed company to achieve a market valuation of £200bn, a landmark achievement for both the pharmaceutical giant and the London Stock Exchange, as investors have been won over by its ambition and success with cancer treatments. The company’s shares rose by 1.1 per cent on Tuesday, propelling its market [...]